The Hematologist | American Society of Hematology

Skip Nav Destination

Diffusion

Dr. Robert Hasserjian sheds light on a study that expanded the spectrum of ALK-rearranged tumors by observing a cohort of 39 cases of ALK-positive histiocytosis.
Podcast

Contributing Editor Dr. Loretta Nastoupil has a conversation with Dr. Melody Smith about a study that explored whether antibiotic exposure or fecal microbiome composition was associated with efficacy and toxicity following anti-CD19 chimeric antigen receptor T-cell therapy in adult patients with B-cell malignancies.
Feature

Editor-in-Chief Dr. Laura Michaelis has a conversation with Dr. Sergiy Klymenko, a hematologist from Kyiv, about how the Russian invasion of Ukraine has affected the way patients with hematologic conditions receive care in a country under attack.

Heparin-Induced Thrombocytopenia in COVID-19

Drs. Surbhi Shah and Alma Habib present the current state of treating heparin-induced thrombocytopenia in patients with COVID-19. Read More

Current Issue

Volume 19,

Issue 4,

July-August 2022

View This Issue

Latest Articles

Rituximab in B-ALL: How Much and for Whom?

Targeting CD22 in Children With Relapsed B-ALL: At Least One Good Thing Happened in 2022

Trust Your Gut: Changes in Intestinal Microbiome Are Associated With Outcomes Following CAR-T Therapy

ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise

Treatment and Prevention of Venous Thromboembolism in Children: Current State and Future Directions

Heparin-Induced Thrombocytopenia in COVID-19

War-Torn Care

In Response to Back to HiDAC

The ASH Advocacy Leadership Institute Returns With First In-person Advocacy Event in Two Years

In Remembrance: Dr. Kwaku Ohene-Frempong

President's Column

Benign, Non-malignant, or Classical?

July 1, 2022
Dr. Jane Winter discusses the shifting tide toward "classical" hematology and how this reflects current realities.

View all president's column articles

Featured Content

Lymphohematopoietic Clones: Are They of Unknown Significance, Indeterminate Potential, or Indeterminate Progression?

Dr. Marshall Lichtman looks at the history and direction of the classification of lymphohematopoietic clones.

Treatment and Prevention of Venous Thromboembolism in Children: Current State and Future Directions

Drs. Marisol Betensky, John Morrison, Anthony Sochet, and Neil Goldenberg review the treatment and prevention of venous thromboembolism in pediatric patients.

FEDORA: The Beginning of a Beautiful Friendship?

Drs. Bethan Psaila and Mary Frances McMullin provide commentary on a study evaluating the tolerability, safety, and activity of fedratinib combined with ropeginterferon alfa-2β in patients with myelofibrosis.

Dr. Robert Hasserjian sheds light on a study that expanded the spectrum of ALK-rearranged tumors by observing a cohort of 39 cases of ALK-positive histiocytosis.

Editor-in-Chief Dr. Laura Michaelis has a conversation with Dr. Sergiy Klymenko, a hematologist from Kyiv, about how the Russian invasion of Ukraine has affected the way patients with hematologic conditions receive care in a country under attack.

Heparin-Induced Thrombocytopenia in COVID-19

Latest Articles

President's Column

Benign, Non-malignant, or Classical?

Featured Content

Lymphohematopoietic Clones: Are They of Unknown Significance, Indeterminate Potential, or Indeterminate Progression?

Treatment and Prevention of Venous Thromboembolism in Children: Current State and Future Directions

FEDORA: The Beginning of a Beautiful Friendship?

ASH Publications

American Society of Hematology

Latest Articles

President's Column

Featured Content

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only